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Sir,
It is not true that ovarian cancer is more than 20% under-registered
in England and Wales as alleged by Macdonald et al (1999).
For the vast majority of cohort studies which use the National
Health Service Central Register (NHSCR) in Southport (part of
the Office for National Statistics (ONS)) to obtain information on
cancer or death, the individuals are ‘flagged’ (i.e. permanently
marked on the register) so that any existing and all future data will
be notified to the researchers. Another process called ‘follow up’
is also possible when subjects are checked against the register on a
single occasion. This of course, is considerably cheaper than flag-
ging, but has the disadvantage that at any one point in time the
cancer information may be incomplete owing to the inevitable
time lags and/or backlogs in the system of cancer registration.
There are three basic reasons why cases of cancer may not have
been notified to researchers at a particular point in time:
1 The case is not (or not yet) registered The case may have been
missed by the relevant regional cancer registry – either when
the person was alive, or if the person died without cancer
being mentioned on the death certificate (in which case a noti-
fication of the death would not have been sent from ONS to
the registry (ONS 1999)). Alternatively, the registry could still
be trying to find out when the cancer was first diagnosed.
2 The case is registered but not yet flagged at NHSCR The case
may have been recorded by the regional cancer registry, but
not forwarded to the National Cancer Intelligence Centre
(NCIC) at ONS Titchfield (perhaps because not all the
required data items were present). Or though sent to the NCIC,
validation checks revealed errors which required returning to
the registry for correction. Other delays can occur when
records do not match automatically on the central register at
Southport and require operator attention.
3 The case is untraced or mistraced at NHSCR In the past, about
3% of records could not be traced, but with recent modifica-
tions both at NHSCR and regional cancer registries, the rate
has now fallen to below 1%. The number of mis-matches is
extremely small, and usually only occurs when the name is a
very common one.
Despite several attempts by ONS staff to explain these problems
and to persuade MacDonald et al to have their cohort flagged so
that they would, eventually, get all the available information, they
insisted on follow up only. Some of the above factors particularly
affected the ovarian screening study.
First, a large proportion of the women in the study lived in the
south east of England. Until quite recently, the methods of regis-
tration used by the Thames Cancer Registry which covers this area
(about a quarter of the population of England) resulted in about
20% of registrations overall being made solely from the informa-
tion on a death certificate (DCO). In 1996, for example, the DCO
rate was 24% overall; for ovarian cancer it was 27% (Thames
Cancer Registry, 1997). As 5 year survival for ovarian cancer is
around 30%, it is likely that there was under-registration of around
10% (Parkin et al, 1994). The proportion of ovarian cancer records
for the rest of England and Wales with zero survival (a mixture of
DCO registrations and true zero survival as a result of findings at
post mortem) is under 5% so under-registration outside the
Thames regions must be very small.
Second, in 1997 when the researchers first notified us of a short-
fall in the information sent to them, not all of the registrations for
1992 and 1993 had been received at ONS. Indeed, the data for
1993 were judged to be complete only in July of last year (1999).
Third, in 1997, there were backlogs in the flagging of cancers at
the NHSCR owing to the high priority work for the Department of
Health of introducing the new NHS numbers. It was only in April
1998 that flagging was complete for cases received up to 1991
incidence year. But by September 1999 NHSCR had caught up and
had flagged all the available cases for 1996 (then about half the
expected eventual total).
In addition, staff at the NHSCR were unable to flag many
members of the cohort because the information supplied by the
researchers was inadequate – for example, lack of full, and accu-
rate, date of birth.
For the reasons given above, MacDonald et al’s analysis should
have been restricted to cases diagnosed before 1991. Of seven
such alleged cases not previously notified to the researchers which
were investigated by ONS in early 1998, two were traced with a
cancer registration (despite both dates of birth supplied by the
researchers being incorrect), and one (with a Scottish address) was
traced by the Scottish NHSCR, leaving only four cases – all of
which, on further checking, were not on the relevant regional
cancer register (three were resident in the Thames regions). At that
time, MacDonald et al said that they had been notified by NHSCR
of four cases (two post-1990) not previously known to them
(rather than the figure of two given in their paper).
It is disappointing that following initial collaboration with ONS,
and strenuous efforts made by our staff to find cases in advance of
the scheduled processing, MacDonald et al chose to publish their
paper without even letting us know that they were doing so, let
alone checking their data and conclusions with us. We stress that
lack of notification of cases to researchers does not necessarily
mean under-registration.
Justified criticisms based on adequate data and taking account
of the relevant circumstances – particularly if accompanied by
constructive suggestions for improvements to our services – are
always welcome. The publication of exaggerated conclusions
based on small numbers of cases without consideration of all the
relevant factors serves only to damage the system of cancer regis-
tration in England and Wales and unfairly bring into question the
quality of the work of the cancer registries and ONS.
Dr M J Quinn, Director, National Cancer Intelligence Centre
Mrs B Botting, Co-ordinator, Medical Research Services
Mr D Foote, Manager, National Cancer Intelligence Centre
Mr A Read, Manager of NHSCR
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Sir,
We read the letter from Quinn et al with interest and are glad to
have an opportunity to acknowledge the cooperation received
from the staff at the ONS throughout our study. The ONS team
made considerable efforts to provide comprehensive reporting of
ovarian cancer cases. Our report was not intended to be a criticism
of the important work performed by the NHSCR.
We reported our comparison of ‘direct’ and NHSCR follow up
for ovarian cancer in order to provide information for the design of
future research studies. Although the two methods of follow up are
complementary, direct follow up identified more cases of ovarian
cancer and identified them in a shorter period of time than was
possible via the NHSCR. Researchers need to be aware of the
issues of incomplete registration and the delay in notification
through the NHSCR and consider the option of using an additional
method of follow up. These issues have major implications for the
design of clinical trials and in this context we hope that the data
provided by our study is of some value.
Quinn et al highlighted the limitations of ‘follow-up’ compared to
‘flagging’ studies via the NHSCR. Whilst these points are entirely
valid they do not explain the eleven cases of ovarian cancer not
identified by the NHSCR in our study. First, follow up was carried
out by the NHSCR in 1997–98, a time point more than five years
after diagnosis of the ovarian cancer cases in our study. Second,
repeated searches were performed by the NHSCR for the eleven
cases both manually and by computer. Although the data originally
supplied to the NHSCR was incomplete for some study participants,
complete data for the relevant eleven cases was resubmitted for
additional searches once the discrepancy was identified. It is
possible that flagging would eventually identify these cases but a
delay of more than five years from study completion to analysis has
major implications for a clinical trial. As noted by Quinn et al a total
of four cases of ovarian cancer reported by the NHSCR were not
identified by direct follow-up. However, the study was limited to
cases diagnosed between 1986 and 1993 because this allowed a 5
year period for data collection by the NHSCR and was the period of
direct follow. Two cases of ovarian cancer identified by the NHSCR
but diagnosed after 1993 were not therefore reported in our paper.
The same applies to three other cases of ovarian cancer diagnosed
after 1993 but not identified by the NHSCR.
It seems sensible for researchers currently designing clinical
studies requiring long-term follow-up to consider using direct
follow up as well as flagging with the NHSCR. Direct follow up is
a rapid and reliable means of identifying cancer cases which
complements information provided by the NHSCR. Major efforts
and numerous changes are being made in the cancer registration
system which are improving the research value of this key
resource. We strongly support investment in cancer registration
and appreciate the efforts being made by staff in the regional
cancer registries and at the ONS. Hopefully in the future the use of
direct follow up in clinical trials will not be necessary!
Nicola MacDonald, Usha Menon, Ian Jacobs
St Bartholomew’s and Royal London School of Medicine and
Dentistry, Queen Mary and Westfield College
Ian Jacobs MD MRCOG Professor of Gynaecological Oncology
St Bartholomew’s Hospital, London EC1A 7BE
doi: 10.1054/ bjoc.2000.1256, available online at http://www.idealibrary.com on 